Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation [1]

Transplantation

Volumn 80, Issue 9, 2005, Pages 1355-

  Mitsuhata, Naoki ^a   Fujita, Ryuji ^a   Ito, Seiichi ^a   Mannami, Makoto ^b   Keimei, Kojima ^b  

^a Kure Kyosai Hospital   (Japan)

^b Uwajima Tokushukai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; AGRANULOCYTOSIS; AUTOIMMUNITY; BLOOD GROUP ABO SYSTEM; CASE REPORT; DIARRHEA; FEMALE; HEMODIALYSIS; HUMAN; HYPOGAMMAGLOBULINEMIA; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; NEUTROPENIA; PLASMAPHERESIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MIDDLE AGED; NEUTROPENIA;

EID: 28544436013     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000184275.81396.45     Document Type: Letter

References (8)

1. Becker YT, Becker BN, Pirsch JD, et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
2. Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediat Transplant 2004; 8: 9-21.
3. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, Splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207-1210.
4. Voog E, Morschhauser F, Solal-Celingny, et al. Neutropenia in patients treated with rituximab. N Engl J Med 2003, 48: 2691-2694.
5. Caiwhatanatorn K, Lee N, Grigg S, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-918.
6. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921-923.
7. Maloney DG, Liles TM, Czerwinski DK, et al. Phase clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466.
8. Vieira C A, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542-548.